ClinicalTrials.gg
Active, not recruitingNCT04592913Updated Dec 24, 2025

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

A Phase 3 interventional study of Durvalumab and FLOT chemotherapy in Gastrointestinal Neoplasms and Esophagogastric Junction, sponsored by AstraZeneca. Active, not recruiting at 156 sites in 20 countries. Open to participants aged 18 Years to 200 Years. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
957
Allocation
Randomized
Ages
18 Years to 200 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Gastrointestinal Neoplasms with a site in Japan — 9 open to participants now, 12 under way, 5 of them phase 3. Gastrointestinal Neoplasms · Japan.

Enrollment
2nd of 23
957 · median 243
Started
2020
with 3 others
Phase 3
9 of 24
3 open now
Primary completion
2024-12
later than 0 of 11 live
Registered
11th of 24
by date
Lead sponsor
1 of 24
AstraZeneca

Among the 24 studies in Gastrointestinal Neoplasms with a site in Japan, this one is the 2nd largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2020, is one of 9 in phase 3, reaches primary completion later than 0 of the 11 other live ones, and was the 11th registered.

Gastrointestinal Neoplasms

696 studies on the registry are indexed under Gastrointestinal Neoplasms; 210 are open to participants now.

Browse Gastrointestinal Neoplasms studies →

Open to participants now

9 of the 24 studies in Gastrointestinal Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 160 Gastrointestinal Neoplasms studies recruiting now, 122 (76%) set no upper age limit and 18 (11%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 200 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Gastrointestinal Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

Read the detailed description

This study investigates treatment of durvalumab or placebo therapy combined with FLOT chemotherapy (flurouroacil + leucovorin + oxaliplatin + docetaxel) given before surgery (neoadjuvant) and durvalumab or placebo therapy combined with FLOT chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer, and also to better understand the studied disease and associated health problems.

03

Conditions studied

  • Gastrointestinal Neoplasms
  • Esophagogastric Junction
04

Who can participate

Ages eligible
18 Years to 200 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients with documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).
  • Patients must undergo radical surgery.
  • No prior anti-cancer therapy for the current .
  • World Health Organization (WHO)/ performance status of 0 or 1 at enrollment.
  • Adequate organ and marrow function.
  • Availability of tumor sample prior to study entry.
  • Must have a of at least 24 weeks.

Key Exclusion Criteria:

  • Patients with peritoneal dissemination or distant .
  • Patients with adenosquamous cell carcinoma, squamous cell carcinoma, or GI stromal tumor.
  • Current or prior use of medication within 14 days before the first dose of durvalumab.
  • to any of the study drugs.
  • History of allogeneic organ transplantation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
957 participants (actual)

Study arms

  • Placebo comparator
    Arm B

    placebo product and FLOT chemotherapy

    Drug: FLOT chemotherapy

  • Experimental
    Arm A

    Durvalumab and FLOT chemotherapy

    Drug: Durvalumab · Drug: FLOT chemotherapy

Interventions

06

What researchers measure

Primary outcomes

  1. Event-free survival (EFS)

    EFS is the time from date of randomization until the date of disease progression or death.

    Time frame: Up to 5 years

Secondary outcomes

  1. To compare Arm A relative to Arm B on overall survival (OS)

    Overall survival is length of time from randomization until the date of death due to any cause.

    Time frame: Up to 5 years

  2. To compare Arm A relative to Arm B on pathological complete response (pCR) rate

    pCR rate is the proportion of patients who have no residual viable tumor in the resected specimens.

    Time frame: Up to 5 years

07

Study locations

156 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Los Angeles, California 90027, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Sylmar, California 91342, United States
  • Research Site
    St. Petersburg, Florida 33705, United States
  • Research Site
    Tallahassee, Florida 32308, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Louisville, Kentucky 40217, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Rochester, New York 14642, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Dallas, Texas 75390, United States
  • Research Site
    Lancaster, Texas 75216, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Buenos Aires, C1431FWO, Argentina
  • Research Site
    Ciudad Autonoma Buenos Aires, 1093, Argentina
  • Research Site
    Ciudad de Buenos Aires, 1280, Argentina
  • Research Site
    Ciudad de Buenos Aires, C1426ANZ, Argentina
  • Research Site
    Rosario, 3101, Argentina
  • Research Site
    Rosario, S2000DEJ, Argentina
  • Research Site
    Charleroi, 6060, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    Edmonton, Alberta t6G1Z2, Canada
  • Research Site
    North York, Ontario M2K 1E1, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9,, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
  • Research Site
    Montreal, H3T 1E2, Canada
  • Research Site
    La Serena, 1720430, Chile
  • Research Site
    Santiago, 7500653, Chile
  • Research Site
    Santiago, 7500921, Chile
  • Research Site
    Talca, 3461341, Chile
  • Research Site
    Temuco, 4800827, Chile
  • Research Site
    Temuco, 4810218, Chile
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    København Ø, 2100, Denmark
  • Research Site
    Odense, 5000, Denmark
  • Research Site
    Avignon, 84918, France
  • Research Site
    Besançon, 25030, France
  • Research Site
    Brest, 29609, France
  • Research Site
    Dijon, 21000, France
  • Research Site
    Lyon, 69373, France
  • Research Site
    Montpellier, 34298, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Nice, 06100, France
  • Research Site
    Paris, 75012, France
  • Research Site
    Paris, 75475, France
  • Research Site
    Paris, 75900, France
  • Research Site
    Rennes, 35033, France
  • Research Site
    Berlin, 13353, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Frankfurt, 60488, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Hamburg, 20249, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Heilbronn, 74078, Germany
  • Research Site
    Jena, 7743, Germany
  • Research Site
    Mainz Am Rhein, 55131, Germany
  • Research Site
    München, 81675, Germany
  • Research Site
    Schweinfurt, 97421, Germany
  • Research Site
    Tübingen, 72016, Germany
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Győr, 9024, Hungary
  • Research Site
    Kecskemét, 6000, Hungary
  • Research Site
    Szekszárd, 7100, Hungary
  • Research Site
    Szolnok, 5004, Hungary
  • Research Site
    Chūōku, 104-0045, Japan
  • Research Site
    Hidaka-shi, 350-1298, Japan
  • Research Site
    Hirakata-shi, 573-1191, Japan
  • Research Site
    Hiroshima, 730-8518, Japan
  • Research Site
    Kashiwa, 277-8577, Japan
  • Research Site
    Kitaadachi-gun, 362-0806, Japan
  • Research Site
    Kochi, 781-8555, Japan
  • Research Site
    Kurume-shi, 830-0011, Japan
  • Research Site
    Nagoya, 464-8681, Japan
  • Research Site
    Niigata, 951-8566, Japan
  • Research Site
    Ogaki-shi, 503-8502, Japan
  • Research Site
    Osaka, 534-0021, Japan
  • Research Site
    Osaka, 541-8567, Japan
  • Research Site
    Suita-shi, 565-0871, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Tokyo, 135-8550, Japan
  • Research Site
    Toyoake-shi, 470-1192, Japan
  • Research Site
    Wakayama, 641-8510, Japan
  • Research Site
    Yokohama, 241-8515, Japan
  • Research Site
    Amsterdam, 1066 CX, Netherlands
  • Research Site
    Eindhoven, 5623EJ, Netherlands
  • Research Site
    Rotterdam, 3015GD, Netherlands

Showing the first 100 of 156 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, Hyung WJ, Wyrwicz L, Oh DY, Omori T, Moehler M, Garrido M, Oliveira SCS, Liberman M, Oliden VC, Smyth EC, Stein A, Bilici M, Alvarenga ML, Kozlov V, Rivera F, Kawazoe A, Serrano O, Heilbron E, Negro A, Kurland JF, Tabernero J; MATTERHORN Investigators. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. N Engl J Med. 2025 Jul 17;393(3):217-230. doi: 10.1056/NEJMoa2503701. Epub 2025 Jun 1. PubMed 40454643 ↗
  • Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore). 2022 May 27;101(21):e29304. doi: 10.1097/MD.0000000000029304. PubMed 35623069 ↗
  • Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, Molena D, Marcovitz M, Ruscica D, Robbins SH, Negro A, Tabernero J. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol. 2022 Jun;18(20):2465-2473. doi: 10.2217/fon-2022-0093. Epub 2022 May 10. PubMed 35535555 ↗
  • Cowzer D, Janjigian YY. Top advances in esophageal/gastroesophageal junction cancers in 2021. Cancer. 2022 May 15;128(10):1894-1899. doi: 10.1002/cncr.34140. Epub 2022 Feb 18. No abstract available. PubMed 35179774 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Dec 2024, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2020
First posted
Oct 19, 2020
StartActual
Nov 17, 2020
Primary completionActual
Dec 20, 2024
CompletionEst.
Sep 27, 2027
Results delay requested
Dec 16, 2025
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04592913
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Nov 17, 2020
Primary completion
Dec 20, 2024
Completion
Sep 27, 2027 (estimated)
Last update
Dec 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion